Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsblue cross blue shield michigan formulary Coverage…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    2026 Healthy Value Enhanced Comprehensive Formulary (Medicare Plus Blue Group PPO & Prescription Blue Group PDP) — Formulary coverage criteria and utilization controls

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the 2026 Medicare Plus Blue Group PPO and Prescription Blue Group PDP formulary describing covered outpatient prescription drugs, applicable coverage rules (prior authorization, step therapy, quantity limits), member rights for exceptions and transition supplies, and who is affected (plan members and prescribers).

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyFormulary coverage criteria — outpatient prescription drugs (Medicare Part D)
    Policy CodePolicy N/A
    Change TypeNo material change (current extraction)
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from the plan before prescribing any drug flagged 'PA' in the formulary.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    05/01/2026Formulary effective date
    31 daysTransition supply
    72/24 hrsException timelines
    Tier 4-5Specialty tier
    MultiplePA presence

    Coverage Criteria and Formulary Rules

    Coverage conditions and required processes

    Covered drugs are generally provided when listed on the formulary and medically necessary, subject to the following rules and conditions.

    Formulary and network rules: Drug is listed on the Medicare Plus Blue Group PPO and Prescription Blue Group PDP formulary and prescription is filled at a network pharmacy

    From formulary description and coverage conditions

    Prior authorization or step therapy: If a drug has prior authorization, step therapy, or quantity limits, coverage requires meeting those requirements or obtaining a plan-approved exception

    Requirements described in the formulary

    Exception approval: Exceptions (including coverage of non-formulary drug, waiving restrictions, or lower tier placement) require a prescriber’s supporting statement showing alternatives are not effective or cause adverse effects; standard decision timeline 72 hours, expedited 24 hours when applicable
    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyFormulary coverage criteria — outpatient prescription drugs (Medicare Part D)
    Policy CodePolicy N/A
    Change TypeNo material change (current extraction)
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from the plan before prescribing any drug flagged 'PA' in the formulary.
    SourceLink
    On This Page
    Coverage Criteria and Formulary RulesCoding, Quantity Limits, and Formulary Note CodesProvider Actions, Prior Authorization, Step Therapy, and DocumentationInitial Therapy and Condition-Specific CriteriaStep Therapy Requirements and RecordsQuantity Limits (QL) by Product and ExamplesDefinitions and AbbreviationsBackground and ScopeBiosimilars and Interchangeability

    Exception criteria and timelines

    Transition supply rules: Members new to the plan or affected by a mid-year change may receive a one-time temporary supply (up to 31 days) while pursuing an exception or transition; special transition protections apply to long-term care residents31 days

    Transition policy protections

    Coverage requirements

    Formulary coverage is determined by drug tier, and may include one or more of the following requirements:

    Formulary Requirement Types: Prior Authorization (PA); Quantity Limits (QL); Step Therapy (ST); Non‑Extended Day Supply (NDS); Oncology Value Management (OVM); B/D designation — coverage depends on meeting any listed requirements and Evidence of Coverage rules

    Definitions and requirement types from formulary introduction

    General formulary coverage with requirements

    Coverage for listed products is subject to formulary tier and any stated Requirements/Limits (e.g., QL, PA, NDS).

    Formulary coverage conditions: The product is listed on the formulary with an assigned Drug Tier and may have Requirements/Limits such as QL (quantity limits), PA (prior authorization), ST (step therapy), or NDS; coverage requires meeting those listed Requirements/Limits

    Examples in formulary: brivaracetam (PA, QL), EPIDIOLEX (PA, QL), various seizure products with PA/QL

    Product-level coverage controls

    Coverage and utilization controls are applied at the product level as shown in Requirements/Limits.

    Formulary requirement: Drug is listed with a Drug Tier and may have Requirements/Limits such as QL, PA, OVM which must be met for coverage

    No patient-level clinical criteria provided in these chunks; controls are per-product

    Coverage conditional on QL/PA/ST

    Coverage for each listed product is tied to the formulary flags shown (Drug Tier, QL, PA, ST).

    Formulary-entry coverage requirements: Member coverage for a listed drug requires adherence to any Quantity Limit (QL) and attainment of Prior Authorization (PA) and/or Step Therapy (ST) when those flags are present in the formulary entry

    Specific QL/PA/ST details are provided per product entry in the formulary

    Formulary coverage entries

    Coverage and utilization management shown as tier, requirements/limits per product

    Formulary coverage lines: Each drug entry lists a Drug Tier and Requirements/Limits; items with 'PA' require prior authorization and those with 'QL(...)' have quantity limits

    Refer to introduction and PA policy sections for process and documentation

    Formulary coverage indicators

    Coverage is indicated by inclusion on the formulary; specific coverage controls are noted as Quantity Limits (QL) and Prior Authorization (PA) where present.

    Formulary inclusion: Drug is listed with a Drug Tier and may have Requirements/Limits (e.g., QL, PA); inclusion indicates potential coverage subject to those controls

    No explicit clinical eligibility criteria provided in this excerpt

    Coverage indicators

    Formulary coverage and utilization management is indicated per drug with Tier assignment and Requirements/Limits

    Formulary entry: Each listed product includes a drug tier and may include Requirements/Limits such as QL, PA, or EX; providers must follow the per-drug Requirements/Limits when seeking coverage

    See individual entries for exact QL or PA requirements

    Formulary coverage lines

    Coverage and utilization controls apply as listed per drug line

    Per-drug formulary rules: Each listed drug line includes a Drug Tier and Requirements/Limits (examples: PA, QL, EX, ST). Coverage is subject to those requirements

    Provider must follow per-drug Requirements/Limits as specified in formulary entries

    If a prescribed drug is not listed on the formulary and an exception is not approved, the plan will not cover that drug. Members should first contact Customer Service to confirm coverage and to obtain a list of covered alternatives to discuss with the prescriber. Members may also request a formulary exception (see plan instructions) if a covered alternative is unsuitable; prescribers must submit supporting clinical information when requesting an exception.

    Entries flagged EX in the Requirements/Limits column are not normally covered under the Medicare Prescription Drug Plan. Payments for drugs marked EX do not count toward total drug costs for catastrophic coverage, and members receiving low‑income subsidy will not receive extra help for drugs marked EX.

    Example of an excluded product in the formulary extract: FEM PH GEL 0.9%; 0.025% is listed with Requirements/Limits = EX, indicating the product is excluded from coverage as shown on the formulary line.

    No additional extract text was provided for this item; see the formulary introduction and the plan’s exception/appeal instructions for details on requesting coverage for non‑formulary drugs.

    The chunks referenced for this segment present drug tier assignments and Requirements/Limits (e.g., QL, PA) but do not list explicit clinical exclusions on those lines; coverage determinations rely on the per‑drug flags shown in the formulary.

    Where no clinical exclusion text appears, coverage limitations are expressed through formulary flags such as QL (quantity limits), PA (prior authorization), and ST (step therapy). Providers and pharmacies must comply with these flags for coverage to be allowed.

    The formulary shows specific products with Requirements/Limits = EX. For example, ASTRINGYN SOLUTION 259MG/GM is listed with Requirements/Limits = EX, indicating exclusion on the formulary.

    Appetite suppressants and weight‑loss agents in the extract show several exclusions: examples include BENZPHEMINE HCL 50MG and multiple formulations of phentermine/related agents where Requirements/Limits = EX, reflecting non‑coverage for those products as listed.

    Entries marked EX in dermatology and topical product groupings indicate exclusion or restricted coverage for that product class (for example, certain pediculicides/scabicides and topical anti‑infectives have EX notations and associated QL values shown on the formulary lines).

    Formulary lines in electrolyte/mineral/vitamin sections include EX flags for select items (for example, DRISDOL CAPSULE 50000UNIT is shown with Requirements/Limits = EX) — these are treated as excluded on the formulary.

    Additional examples of excluded genitourinary and related products appear in the extract: several erectile dysfunction injectables/tablets and certain fertility or reproductive therapy lines are shown with Requirements/Limits = EX on their formulary entries (see the listed drug lines for specific products).

    No source text was associated with this inventory item; refer to the plan’s introduction pages for definitions of symbols and for a complete list of excluded items in the full formulary.

    The extract does not include explicit 'Not Medically Necessary' (NMN) declarations for listed products. Instead, coverage decisions are expressed via the formulary flags (PA, QL, ST, EX); absence of an NMN statement means clinicians should follow the per‑drug Requirements/Limits and the payer’s prior authorization and exception processes.

    These chunks do not expressly mark specific products as 'Not Medically Necessary.' Coverage is driven by the presence of flags such as PA, QL, and ST on each formulary line rather than NMN language in this excerpt.

    Individual examples of formulary exclusions or exceptions are provided on product lines (for instance, ANALPRAM HC CREAM and several topical classes are shown with Requirements/Limits = EX), indicating those products are not covered as listed.

    Coding, Quantity Limits, and Formulary Note Codes

    Quantity Limit Codesmixed
    QL(180 EA per 90 days)Quantity limit for celecoxib capsule 200mg, 400mg
    QL(270 EA per 90 days)Quantity limit for celecoxib capsule 100mg
    QL(540 EA per 90 days)Quantity limit for celecoxib capsule 50mg
    QL(600 ML per 30 days)Quantity limit for diclofenac sodium external solution 1.5%
    QL(4 EA per 28 days)Quantity limit for buprenorphine patch weekly
    QL(15 EA per 30 days)Quantity limit for fentanyl patch 72 hour
    QL(3720 ML per 31 days)Quantity limit for methadone HCl solution 5mg/5ml
    QL(31 EA per 31 days)Quantity limit for tramadol HCl ER 100/200/300mg (example)
    QL(93 EA per 31 days)Quantity limit for morphine sulfate ER other strengths
    QL(62 EA per 31 days)Quantity limit for oxymorphone ER
    1–10 of 17
    1/2
    Formulary Note Codesmixed
    PAPrior Authorization
    STStep Therapy
    EXNot normally covered
    NDSNon-Extended Day Supply
    OVMOncology Value Management
    B/DMay be covered under Part B or D depending on circumstances
    Selected covered drug entries (partial)NDC_like_textCovered
    buprenorphine hcl/naloxone hcl 8mg/2mg tablet sublingualTier 1; QL(360 EA per 90 days)
    buprenorphine hcl/naloxone hcl 2mg/0.5mg tablet sublingualTier 1; QL(630 EA per 90 days)
    buprenorphine hcl tablet sublingual 8mgTier 1; QL(360 EA per 90 days)
    buprenorphine hcl tablet sublingual 2mgTier 1; QL(630 EA per 90 days)
    naloxone (KLOXXADO) liquid 8MG/0.1MLTier 3; QL(12 EA per 90 days)
    Specialty / restrictedNDC_like_textCovered
    ARIKAYCE SUSPENSION 590MG/8.4MLTier 5; Requirements/Limits = PA
    VOQUEZNA DUAL PAK 500MG;20MGTier 4; Requirements/Limits = QL(336 EA per 90 days); PA
    FEM PH GEL 0.9%;0.025%Tier 2; Requirements/Limits = EX
    Listed antibiotics and formulationsNDC/multiformulation
    levofloxacin 500mg/100ml; 750mg/150ml; injection 25mg/ml; oral solution 25mg/ml; tablets 250mg/500mg/750mglevofloxacin formulations listed with tiers and requirements/limits
    Anticonvulsants and seizure-related productsmixed
    brivaracetam, levetiracetam, clobazam, perampanel, diazepam gel, valproic acid, lacosamide, rufinamide, vigabatrin, etc.Anticonvulsant products and formulations with tiers and requirement notes (PA, QL, NDS)
    Antidementia agentsmixed
    donepezil, memantine, galantamine, rivastigmine, NAMZARIC, MEMANTINE HCL TITRATION PAKAntidementia agents with tiers and QL entries
    Antidepressantsmixed
    AUVELITY, bupropion ER, EXXUA, ZURZUVAEAntidepressant products with tiers and QL/ST indicators
    Selected Quantity Limit annotations in excerptmixed
    QL(98 EA per 365 days)Quantity limit for MEMANTINE HCL TITRATION PAK TABLET 0
    QL(90 EA per 90 days)Quantity limit for memantine hydrochloride er capsule extended release (various strengths)
    QL(1080 ML per 90 days)Quantity limit for memantine hydrochloride solution 2mg/ml
    Additional Quantity Limitsmixed
    QL(31 EA per 31 days)Quantity limit example (e.g., EMSAM PATCH)
    QL(180 EA per 90 days)Common 90-day EA quantity limit (multiple tablets)
    QL(6 ML per 84 days)Quantity limit for AIMOVIG INJECTION 140MG/ML
    Selected migraine therapiesmixedCovered
    UBRELVY 100MG, 50MGUBRELVY TABLET 100MG, 50MG; Tier 5; Requirements: QL(16 EA per 30 days); PA
    dihydroergotamine mesylate solution 4mg/mldihydroergotamine mesylate solution 4mg/ml; Tier 5; Requirements: QL(24 ML per 90 days); PA
    naratriptan hcl tablet 2.5mgnaratriptan hcl tablet 2.5mg; Tier 2; Requirements: QL(24 EA per 90 days)
    rizatriptan benzoate ODT 5mgrizatriptan benzoate odt tablet disintegrating 5mg; Tier 2; Requirements: QL(162 EA per 90 days)
    sumatriptan succinate injection 4mg/0.5ml, 6mg/0.5mlSUMATRIPTAN SUCCINATE REFILL INJECTION 4MG/0.5ML, 6MG/0.5ML; Tier 4; Requirements: QL(27 ML per 90 days)
    sumatriptan succinate tablet 50mgsumatriptan succinate tablet 50mg; Tier 2; Requirements: QL(108 EA per 90 days)
    Antimycobacterials and antitubercularsmixedCovered
    PRETOMANID 200MGPRETOMANID TABLET 200MG; Tier 4; Requirements: QL(90 EA per 90 days); PA
    dapsone 100mg, 25mgdapsone tablet 100mg, 25mg; Tier 3; Requirements: none listed
    rifabutin capsule 150mgrifabutin capsule 150mg; Tier 4
    isoniazid syrup 50mg/5mlisoniazid syrup 50mg/5ml; Tier 4
    Selected dermatology and oncology agentsmixedCovered
    VALCHLOR GEL 0.016%VALCHLOR GEL 0.016%; Tier 5; Requirements: PA; OVM
    ZEPZELCA INJECTION 4MGZEPZELCA INJECTION 4MG; Tier 5; Requirements: PA
    abiraterone acetate 250mgabiraterone acetate tablet 250mg; Tier 4
    lenalidomide capsule (various strengths)lenalidomide capsule 2.5mg–25mg; Tier 5; Requirements: QL(31 EA per 31 days); PA
    Antineoplastics and related agentsmixedCovered
    pomalidomide capsulepomalidomide capsule 1mg–4mg; Tier 5; Requirements: PA; OVM
    THALOMID 50/100MGTHALOMID CAPSULE 50MG, 100MG; Tier 5; Requirements: PA; OVM
    GEMCITABINE injectionGEMCITABINE HYDROCHLORIDE INJECTION (multiple strengths); Tier 3
    mercaptopurine suspension 2000mg/100mlmercaptopurine suspension 2000mg/100ml; Tier 5
    Selected specialty oncology products (large group)mixedCovered
    LONSURF TABLETLONSURF TABLET (multiple strengths); Tier 5; Requirements: PA; OVM
    OGSIVEO TABLET 50/100/150MGOGSIVEO TABLET 50MG, 100MG, 150MG; Tier 5; Requirements: PA; OVM
    ONUREG TABLET 200/300MGONUREG TABLET 200MG, 300MG; Tier 5; Requirements: PA; OVM
    IBRANCE (palbociclib)IBRANCE CAPSULE/TABLET 75/100/125MG; Tier 5; Requirements: PA; OVM
    IMBRUVICA (ibrutinib)IMBRUVICA CAPSULE/TABLET/SUSPENSION (multiple strengths); Tier 5; Requirements: PA; OVM
    ROZLYTREK capsuleROZLYTREK CAPSULE 100MG, 200MG; Tier 5; Requirements: QL(93 EA per 31 days); PA; OVM
    RUBRACA tabletRUBRACA TABLET 200MG/250MG/300MG; Tier 5; Requirements: QL(124 EA per 31 days); PA
    Formulary drug entries and limitsmixed
    SUSTENNA INJECTION 39MG/0.25MLlisted with QL(0.25 ML per 28 days)
    INVEGA SUSTENNA INJECTION 78MG/0.5MLDrug Tier = 5; QL(0.5 ML per 28 days); ST
    INVEGA SUSTENNA INJECTION 117MG/0.75MLDrug Tier = 5; QL(0.75 ML per 28 days); ST
    INVEGA SUSTENNA INJECTION 156MG/MLDrug Tier = 5; QL(1 ML per 28 days); ST
    INVEGA SUSTENNA INJECTION 234MG/1.5MLDrug Tier = 5; QL(1.5 ML per 28 days); ST
    INVEGA TRINZA INJECTION 273MG/0.88MLDrug Tier = 5; QL(0.88 ML per 90 days); ST
    INVEGA TRINZA INJECTION 410MG/1.32MLDrug Tier = 5; QL(1.32 ML per 90 days); ST
    INVEGA TRINZA INJECTION 546MG/1.75MLDrug Tier = 5; QL(1.75 ML per 90 days); ST
    INVEGA TRINZA INJECTION 819MG/2.63MLDrug Tier = 5; QL(2.63 ML per 90 days); ST
    lurasidone hydrochloride tablet 20mg/40mg/60mg/120mgDrug Tier = 3; QL(31 EA per 31 days)
    1–10 of 37
    1/4
    Example Quantity Limitsmixed
    QL(168 EA per 180 days)oseltamivir phosphate capsule 30mg quantity limit
    QL(84 EA per 180 days)oseltamivir phosphate capsule 45mg, 75mg quantity limit
    QL(1050 ML per 180 days)oseltamivir phosphate suspension reconstituted 6mg/ml quantity limit
    QL(180 EA per 90 days)RELENZA DISKHALER quantity limit
    Coronavirus agents QLsmixed
    QL(40 EA per 30 days)LAGEVRIO CAPSULE 200MG quantity limit
    QL(22 EA per 30 days)PAXLOVID TABLET THERAPY PACK (300mg-100mg day1; 150mg-100mg days2-5) quantity limit
    QL(60 EA per 30 days)PAXLOVID alternative pack quantity limit
    Selected GLP-1/weight management QLs and PAmixed
    QL(27 ML per 90 days); PAliraglutide injection quantity limit and prior auth
    QL(2 ML per 28 days); PAMOUNJARO injection quantity limit and prior auth
    QL(3 ML per 28 days); PAOZEMPIC injection quantity limit and prior auth
    Formulary requirement codes and examplesmixed
    QL(180 EA per 90 days)Quantity limit example shown for dabigatran etexilate capsule 150mg, 75mg
    QL(148 EA per 365 days)Quantity limit example for ELIQUIS STARTER PACK TABLET THERAPY PACK 5MG
    QL(194 EA per 90 days)Quantity limit example for ELIQUIS and XARELTO formats
    QL(1164 EA per 90 days)Quantity limit for ELIQUIS TABLET SOLUBLE 0.5MG (3x0.5mg=1.5mg dose)
    QL(1552 EA per 90 days)Quantity limit for ELIQUIS TABLET SOLUBLE 0.5MG (4x0.5mg=2mg dose)
    QL(2700 ML per 90 days)Quantity limit for rivaroxaban suspension reconstituted 1mg/ml
    PAPrior authorization requirement flag shown next to some products
    OVMProgram flag shown for some agents (FULPHILA, NEULASTA ONPRO, NEULASTA, ZARXIO)
    EXExcluded — e.g., ASTRINGYN SOLUTION listed with Requirements/Limits = EX
    Quantity limits shownmixed
    QL(2 ML per 28 days)Quantity limit for PRALUENT (2 mL per 28 days)
    QL(31 EA per 31 days)Quantity limit for VYNDAMAX (31 EA per 31 days)
    QL(1350 ML per 90 days)Quantity limit for CORLANOR solution
    Prior authorization flagsmixed
    PAPrior authorization required flag shown adjacent to some products
    Formulary drug entries (no procedure/diagnosis codes in this excerpt)mixed
    No codes listed
    Selected brand product codes (non-NDC identifiers as listed)mixed
    OTEZLA XR 75MGOtezla XR tablet extended release 24 hour 75mg — QL(31 EA per 31 days); PA
    OTEZLA 20MG, 30MGOtezla tablets — QL(62 EA per 31 days); PA
    OTEZLA/OTEZLA XR 28 DAY PACKTherapy pack — QL(28 EA per 28 days); PA
    Electrolyte/mineral modifiers and related agentsmixed
    tolvaptan 15mg, 30mgtolvaptan tablet — QL(124 EA per 31 days); PA; generic Jynarque
    deferasirox 125mg/250mg/500mg/180mg/360mgdeferasirox tablets — some strengths require PA as listed
    Quantity limits and utilization controlsmixed
    QL(124 EA per 31 days)Quantity limit example for tolvaptan / VYNDAQEL etc
    QL(31 EA per 31 days)Quantity limit example (tolvaptan Samsca)
    QL(62 EA per 31 days)Quantity limit example (tolvaptan 30mg)
    QL(270 EA per 90 days)Quantity limit example for LOKELMA/VELTASSA
    QL(180 EA per 90 days)Quantity limit example for many GI agents
    QL(93 EA per 31 days)Quantity limit for XIFAXAN 550mg
    QL(62 EA per 31 days)Quantity limit example for XPHOZAH
    QL(12 EA per 30 days)Quantity limit for VOWST
    QL(6 EA per 30 days)Quantity limit example for injectable erectile dysfunction agents
    STStep therapy requirement (pancreatic enzyme preparations)
    Transition/temporary supply limit
    Temporary transition/early supplyOne-time temporary 31-day supply is provided for drugs not on the formulary or with new restrictions while member pursues exception or transition (31‑day supply).
    Long‑term care emergency supplyIf a long‑term care resident needs a non‑formulary or restricted drug, a 31‑day emergency supply will be provided while pursuing a formulary exception.
    Eligibility window for transitional coverageMembers new to the plan may receive transition coverage for drugs not on formulary or with new restrictions during the first 108 days of membership.
    Refill/dispense rule during transitionIf the prescription is written for fewer days, refills may be allowed to provide up to a maximum 31‑day supply during the transition period.
    Waiver of early refill limits for care transitionsWhen moving into/out of long‑term care, skilled nursing facility, or upon hospital discharge, limits on early prescription refills may be waived to ensure medication access during the transition.
    Quantity limits examples
    Examples of EA per time QLsQL examples across the formulary include QL(31 EA per 31 days), QL(180 EA per 90 days), QL(360 EA per 90 days), QL(270 EA per 90 days).
    High-volume ML limitsLiquid/solution quantity limits include large ML caps such as QL(3720 ML per 31 days) for methadone solution and QL(2480 ML per 31 days) for hydromorphone liquid.
    90-day QL examples for opioids and othersExamples include QL(372 EA per 31 days) for some methadone tablets (reported per 31 days) and QL(360 EA per 90 days) for certain buprenorphine products.
    Buprenorphine/naloxone QLsSublingual tablets/films: QL(360 EA per 90 days) or QL(630 EA per 90 days) depending on strength/formulation.
    Naloxone/OPVEE QL exampleOpioid reversal agents: KLOXXADO/OPVEE shown with QL(12 EA per 90 days).
    Quantity limits examples (specific QLs)
    ELIQUIS tablet-soluble QLs (soluble 0.5mg)QL(1164 EA per 90 days) and QL(1552 EA per 90 days) shown for ELIQUIS tablet soluble 0.5mg (different dosing equivalents).
    ELIQUIS starter/therapy pack QLELIQUIS STARTER PACK: QL(148 EA per 365 days); ELIQUIS tablet 2.5mg: QL(180 EA per 90 days).
    Rivaroxaban suspension ML QLRivaroxaban suspension reconstituted 1mg/ml: QL(2700 ML per 90 days).
    Quantity limits examples (ML/EA examples)
    INVEGA SUSTENNA injection QLs (various strengths)INVEGA SUSTENNA injections listed with specific mL QLs per 28 days: 0.25 mL, 0.5 mL, 0.75 mL, 1 mL, 1.5 mL per the strength shown; ST applies.
    INVEGA TRINZA injection QLs (various strengths)INVEGA TRINZA injections listed with QLs per 90 days by presentation: 0.88 mL, 1.32 mL, 1.75 mL, 2.63 mL corresponding to listed strengths.
    Lurasidone tablet QLsLurasidone hydrochloride tablets: QL(31 EA per 31 days) for 20–120mg strengths; QL(62 EA per 31 days) for 80mg strength.
    REXULTI / PERSERIS / VRAYLAR examplesPERSERIS injection: QL(1 EA per 30 days); REXULTI: QL(31 or 62 EA per 31 days) with ST on some strengths; VRAYLAR capsules: QL ranges (31–93 EA per 31 days) and may be ST.
    Example quantity limits (migraine examples)
    Acute migraine QLs (triptans & gepants)UBRELVY: QL(16 EA per 30 days); naratriptan 2.5mg: QL(24 EA per 90 days); sumatriptan injection: QL(27 ML per 90 days).
    Rizatriptan ODT/tablet QLsRizatriptan benzoate tablets/ODT: QL(162 EA per 90 days) for 5mg; QL(81 EA per 90 days) for 10mg strengths.
    Sumatriptan tablet QLsSumatriptan succinate tablets 25/50/100mg: examples include QL(108 EA per 90 days) for 50mg and QL(54 EA per 90 days) for 100mg.
    High QL examples
    High EA/ML QL examples (soluble/tablet conversions)Examples include QL(194 EA per 90 days) and very large soluble tablet QLs like QL(1164 EA per 90 days) and QL(1552 EA per 90 days) noted for ELIQUIS soluble formulations.
    Large suspension ML limitsRivaroxaban suspension: QL(2700 ML per 90 days); lacosamide solution and other liquids show ML-based QLs in the hundreds to thousands of mL per period.
    Common 90‑day EA capsMany oral tablet classes use QL examples such as QL(90 EA per 90 days), QL(180 EA per 90 days), QL(360 EA per 90 days) depending on therapy and strength.
    Examples of quantity limits (various formulations)
    Tolvaptan and related QLsTolvaptan 15mg: QL(31 EA per 31 days); tolvaptan 30mg: QL(62 EA per 31 days); some tolvaptan listings show QL(124 EA per 31 days) for generic Jynarque with PA.
    Sevelamer / LOKELMA / phosphate binder QLsSevelamer carbonate packets/tablets: QL examples include 180 EA per 90 days, 270 EA per 90 days, and 1620 EA per 90 days; LOKELMA packet QLs include 270 EA and 94 EA per 90 days.
    XIFAXAN and VOWST QLsXIFAXAN 550mg: QL(93 EA per 31 days); VOWST capsule: QL(12 EA per 30 days).
    Genitourinary/ED QLsAlfuzosin ER 10mg: QL(90 EA per 90 days); tadalafil 2.5mg: QL(180 EA per 90 days); tadalafil 5mg: QL(90 EA per 90 days); many injectable ED agents QL(6 EA per 30 days) and some marked EX.
    Quantity limits examples (ML/EA examples)
    Oseltamivir and influenza antiviral QLsOseltamivir capsule 30mg: QL(168 EA per 180 days); oseltamivir 45/75mg: QL(84 EA per 180 days); oseltamivir suspension: QL(1050 ML per 180 days).
    Coronavirus antivirals (LAGEVRIO, PAXLOVID) QLsLAGEVRIO capsule 200mg: QL(40 EA per 30 days). PAXLOVID therapy packs: QL examples 22–60 EA per 30 days depending on pack option (22, 40, or 60).
    Liraglutide ML QLLiraglutide injection 6mg/mL: QL(27 ML per 90 days); PA applies.
    MOUNJARO ML QLMOUNJARO injections (multiple strengths in 0.5 mL presentations): QL(2 ML per 28 days); PA applies.
    High/complex QL examples
    Eliquis soluble tablet QLs (three listings)QL(194 EA per 90 days), QL(1164 EA per 90 days), and QL(1552 EA per 90 days) appear for various ELIQUIS soluble/tablet formulations and dosing equivalents.
    ELIQUIS starter packELIQUIS STARTER PACK: QL(148 EA per 365 days).
    Dabigatran QL exampleDabigatran etexilate capsule 150mg/75mg: QL(180 EA per 90 days).
    Sample quantity limits (examples consolidated)
    Most actionable: quantity‑limit and PA adherenceCoverage requires meeting per‑drug Requirements/Limits (e.g., QL and PA). Examples include INVEGA SUSTENNA/TRINZA ML QLs, liraglutide QL(27 ML per 90 days) with PA, PRALUENT QL(2 ML per 28 days) with PA, and PAXLOVID pack QLs (22–60 EA per 30 days). Providers must obtain PA and respect QLs to avoid denial.
    Specific injectable ML QLs to noteINVEGA SUSTENNA: 0.25–1.5 mL per 28 days by strength; INVEGA TRINZA: 0.88–2.63 mL per 90 days by strength; PRALUENT: QL(2 ML per 28 days).
    Common tablet EA QLs to referenceFrequent EA QLs include QL(31 EA per 31 days), QL(90 EA per 90 days), QL(180 EA per 90 days), QL(360 EA per 90 days), and product‑specific values (e.g., LYBALVI QL(30 EA per 30 days)).
    Large liquid/suspension QLsExamples: BRIVIACT solution QL(620 ML per 31 days); Rivaroxaban suspension QL(2700 ML per 90 days); methadone solution QL(3720 ML per 31 days).
    Antiviral/coronavirus pack QLsLAGEVRIO QL(40 EA per 30 days); PAXLOVID therapy pack options QL(22/40/60 EA per 30 days depending on pack).

    Provider Actions, Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior Authorization required

    Prior authorization is required for drugs marked "PA" in the formulary; obtain plan approval before dispensing or the plan may not cover the drug.

    • Examples in the formulary include ARIKAYCE Suspension (Requirements/Limits = PA) and many specialty agents flagged PA.
    Prior Authorization

    Prior authorization

    Obtain prior authorization per the plan's Requirements/Limits for products labeled "PA"; lack of approval may lead to noncoverage.

    • Prescribers must follow the PA process described in the plan materials and may be asked to submit clinical justification, diagnosis, and quantity information.
    Prior Authorization

    PA required for select specialty/high-tier drugs

    For high‑tier and specialty products flagged "PA" (e.g., ARIKAYCE, VOQUEZNA), submit prior authorization prior to dispensing because these products require plan approval.

    • VOQUEZNA dual/triple pak: Requirements/Limits = QL(336 EA per 90 days); PA.
    • ARIKAYCE Suspension 590mg/8.4mL: Requirements/Limits = PA.
    Prior Authorization

    PA required for selected formulary items

    Obtain prior authorization for formulary items marked "PA"; multiple products across therapeutic areas in the formulary are PA‑flagged and require approval before coverage.

    • Examples include brivaracetam products (QL and PA), EPIDIOLEX (QL; PA) and many anticonvulsant listings with PA noted.
    Prior Authorization

    Prior authorization required (examples)

    Prior authorization is required for medications annotated with "PA" in the Requirements/Limits column; follow the plan PA procedures before filling.

    • Examples in this excerpt: AUVELITY, EXXUA, ZURZUVAE and other listed agents with PA flags.
    Prior Authorization

    Prior authorization required (multiple listed drugs)

    Multiple listed drugs include a "PA" flag; providers must obtain prior authorization per each product's Requirements/Limits prior to coverage.

    • Selected oncology and targeted agents (e.g., VALCHLOR Gel, ZEPZELCA, ROZLYTREK, RUBRACA) show PA and often OVM requirements.
    Prior Authorization

    PA required for flagged drugs (LYBALVI example)

    Products flagged with PA and a QL (e.g., LYBALVI) require submission of prior authorization and adherence to the stated quantity limit for coverage.

    • LYBALVI Tablet: Requirements/Limits = QL(30 EA per 30 days); PA.
    Prior Authorization

    Antivirals and specialty agents requiring PA

    Antivirals and other specialty antiviral agents shown with "PA" require prior authorization before coverage; submit supporting documentation per PA process.

    • Examples include LIVTENCITY, PREVYMIS, MAVYRET, VOSEVI and selected coronavirus antivirals with QLs and PA.
    Prior Authorization

    Prior authorization required for select agents (liraglutide example)

    Certain GLP‑1 and related antidiabetic agents are marked with PA and specific ML QLs; obtain prior authorization and document quantity requested.

    • liraglutide injection: QL(27 ML per 90 days); PA.
    • MOUNJARO injection: QL(2 ML per 28 days); PA.
    Prior Authorization

    Prior authorization required for select specialty agents

    Select specialty agents and topical products in this section carry a "PA" requirement; secure prior authorization per the formulary entry prior to dispensing.

    • EUCRISA ointment and EBGLYSS injection list QLs and PA; deferasirox products shown with PA.
    Prior Authorization

    Prior authorization required for select products (PRALUENT/VERQUVO examples)

    Certain high‑cost specialty products (examples: PRALUENT, VERQUVO) are indicated with "PA" and specific QLs; submit PA and respect the stated quantity limits.

    • PRALUENT Injection: QL(2 ML per 28 days); PA.
    • VERQUVO Tablet 10mg: QL(30 EA per 30 days); PA.
    Prior Authorization

    Prior authorization required (PRALUENT, VERQUVO examples)

    Drugs labeled "PA" require prior authorization before coverage; review each product's Requirements/Limits and submit PA documentation when present.

    • Examples include PRALUENT and multiple specialty cardiology and oncology agents with PA flags.
    Prior Authorization

    Prior authorization required (topical and others)

    Topical dermatologic agents and other listed products showing QL/PA must follow stated PA and quantity controls; obtain PA when the Requirements/Limits column lists "PA".

    • EUCRISA ointment: Requirements/Limits include QL and PA; clobetasol and other topicals show QLs which must be observed.
    Prior Authorization

    PA for select electrolyte/modifier agents

    Electrolyte/mineral modifiers such as deferasirox and tolvaptan are indicated with PA (and QL); secure prior authorization and adhere to quantity limits.

    • deferasirox tablet formulations: Requirements/Limits = PA.
    • tolvaptan tablet 15mg (generic Jynarque): QL(124 EA per 31 days); PA.
    Prior Authorization

    Prior authorization required for listed PA drugs

    Multiple agents in the extract are shown with a "PA" flag; providers must request prior authorization per each product's Requirements/Limits prior to coverage.

    • Examples across sections include trientine, AURYXIA, ferric citrate and many specialty/orphan drugs requiring PA.
    Prior Authorization

    Prior authorization required for listed products (tadalafil/growth hormones examples)

    Some listed products (e.g., tadalafil 2.5mg/5mg, growth hormone/fertility agents) require prior authorization; check the Requirements/Limits column and submit PA if shown.

    • tadalafil 2.5mg: QL(180 EA per 90 days); PA.
    • GENOTROPIN injections: Requirements/Limits = PA.
    Step Therapy

    Step therapy requirement

    When a product is marked "ST" (step therapy) in the formulary, the member must try the required preferred agent(s) first and the provider must document trial/failure or request an exception.

    • Step therapy examples in the formulary include EXXUA titration pack and TRINTELLIX tablets which are annotated ST.
    Step Therapy

    Step therapy

    If a drug line includes the "ST" flag, follow the plan's step‑therapy sequence; document trial and failure of required agent(s) or submit an approved exception.

    • EXXUA Titration Pack: Requirements/Limits = QL(32 EA per 14 days); ST.
    • TRINTELLIX tablets: Requirements/Limits include ST designation.
    Step Therapy

    Step therapy (placeholder/empty label)

    Medications annotated "ST" require the plan's step‑therapy sequence to be met prior to coverage; providers must document prior therapy or request an exception.

    • Examples: EXXUA products (ST); TRINTELLIX tablets (ST).
    Step Therapy

    Step therapy (placeholder/empty chunk_indices)

    Medications with "ST" flagged in the formulary require that the member try the specified preferred agent(s) first; submit documentation of trial/failure or an exception request for coverage.

    • INVEGA SUSTENNA and PERSERIS injections are also listed with ST where applicable.
    Step Therapy

    Step therapy required (EXXUA/TRINTELLIX examples)

    Step therapy applies to products marked "ST"; document prior use of preferred agents or request a formulary/tiering exception with prescriber rationale when necessary.

    • PANCREAZE entries show ST for certain strengths; providers must follow the ST requirement for coverage.
    Note

    Utilization management note (OVM present)

    Some oncology agents include an OVM flag in addition to PA; follow the Oncology Value Management process (OncoHealth) and submit required documentation for PA/OVM as indicated.

    • Many antineoplastics list Requirements/Limits = PA; OVM and require submission through the Oncology Value Management program.
    Step Therapy

    Step therapy required for ST-flagged drugs (Invega/Perseris examples)

    ST‑flagged antipsychotic long‑acting injectables and related products require step therapy where shown; obtain documentation of required prior therapy or submit an exception.

    • INVEGA SUSTENNA injections and PERSERIS injection: Requirements/Limits include ST and QLs.
    Step Therapy

    Step therapy not specified in this segment

    No explicit step‑therapy algorithm is provided in this extract; where ST is listed, follow the formulary's step requirements and document trials or request exceptions.

    • The introduction pages and plan PA/ST documents provide procedural details for exceptions and step therapy.
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Exception supporting documentation required

    When requesting an exception (formulary or tiering), the prescriber must provide a supporting statement explaining medical reasons; the plan typically decides within 72 hours of receiving the prescriber's statement (24 hours for expedited requests).

    • Prescriber supporting statement is required to request waiving PA, ST, or QL; timelines: 72 hours standard, 24 hours expedited if requested and approved.
    Documentation Required

    B/D documentation (Part B vs Part D determination)

    For drugs that may be covered under Part B or Part D, submit information describing the drug’s use and setting (B/D documentation) so the plan can determine appropriate coverage.

    • The B/D designation in the formulary indicates additional information may be required to adjudicate coverage under Part B vs Part D.
    Billing Rule

    Quantity limits documented (buprenorphine/naloxone, naloxone examples)

    Adhere to stated quantity limits (QL) when dispensing products; for QL‑flagged drugs (e.g., buprenorphine/naloxone, naloxone, many others) provide quantities consistent with the QL or obtain PA to exceed limits.

    • Buprenorphine/naloxone tablet QLs: QL(360 EA per 90 days) or QL(630 EA per 90 days) depending on strength.
    • KLOXXADO liquid: QL(12 EA per 90 days).
    Documentation Required

    Prior authorization documentation (examples)

    When a formulary entry lists "PA" in Requirements/Limits, providers must submit prior authorization documentation (clinical justification, diagnosis, and quantity) per the plan’s PA process before the drug will be covered.

    • Examples: brivaracetam listings require QLs and PA; the plan's prior authorization procedures are referenced in the introduction material.
    Documentation Required

    PA process reference

    Use the plan's prior authorization process for items marked "PA"; follow the procedural instructions in the formulary introduction and submit requested supporting documentation.

    • Refer to the introduction pages for symbols/abbreviations and to the plan's PA process for required submission details.
    Note

    Formulary requirements (Requirements/Limits fields)

    Formulary entries list Requirements/Limits fields (PA, QL, ST); providers must meet these per‑drug requirements when submitting claims or prior authorization requests.

    • Check each product line in the formulary for its specific Requirements/Limits and follow those controls.
    Documentation Required

    Supporting documentation for PA

    Prescribers and pharmacies must supply documentation to support PA requests for drugs flagged "PA" in the formulary; this includes clinical justification and evidence of prior therapies where applicable.

    • Products flagged PA (e.g., LYBALVI, eltrombopag, PROCRIT) require submission of clinical justification and quantity information.
    Note

    Refer to introduction for symbols/abbreviations

    Refer to the formulary introduction pages for the definitions of symbols and abbreviations (PA, QL, ST, EX, OVM, B/D) and for guidance on documentation standards for authorization requests.

    • The introduction explains code meanings and procedural expectations for PA/ST/QL documentation.
    Documentation Required

    Documentation for PA

    When a product's Requirements/Limits show "PA" or a QL, submit prior authorization documentation consistent with the plan's requirements (clinical rationale, diagnosis, and quantity) to avoid denial.

    • Products such as eltrombopag, PRALUENT, and VERQUVO list PA and QLs — documentation must support the request to obtain coverage.
    Billing Rule

    Quantity limits present (operational note)

    Quantity limits (QL) shown in the formulary specify maximum units per time period; do not exceed QLs without obtaining prior authorization to avoid claim adjustment or denial.

    • Examples: QL(180 EA per 90 days), QL(2 ML per 28 days), QL(31 EA per 31 days).
    Documentation Required

    Documentation for PA/QL (providers should supply consistent documentation)

    When a product lists QL or PA, providers should submit consistent documentation (prescription details, clinical justification, and quantity) with the PA request to support coverage.

    • Adhering to stated QLs and providing required PA documentation reduces risk of denial.
    Note
    Note
    Billing Rule

    Provide PA and respect QL

    Providers must obtain prior authorization where indicated and adhere to quantity limits; failure to do so may result in the plan not covering the drug or claims being denied.

    • This is emphasized throughout the formulary: PA is required before filling certain drugs and absence of approval may lead to noncoverage.
    Denial Risk

    Prior Authorization denials risk

    Failure to obtain required prior authorization or to meet listed Requirements/Limits may result in coverage denial; obtain PA and document compliance with QLs/ST to avoid denials.

    • The formulary states that drugs requiring PA will not be covered without approval and that missing PA may lead to denial.
    Denial Risk

    Prior Authorization requirement (denial risk emphasis)

    If prior authorization is required and not obtained, the plan may deny coverage for the drug; always verify PA status before dispensing PA‑flagged products.

    • The plan explicitly states lack of approval may result in the plan not covering the drug.
    Note

    Prior authorization / Exclusion flags present (examples)

    PA, EX, and OVM flags in the formulary indicate coverage controls; drugs with these flags (e.g., ARIKAYCE, VOQUEZNA, products marked EX) require attention to PA or may be excluded/denied when criteria are unmet.

    • ARIKAYCE Suspension: Requirements/Limits = PA.
    • VOQUEZNA packs: QL(...) and PA.
    • Entries marked EX are not normally covered.
    Denial Risk

    PA requirement implies denial risk

    Requests for drugs listed with 'PA' and without meeting PA requirements may be denied; ensure PA is approved before dispensing.

    • The formulary warns that requests for PA‑flagged drugs not meeting requirements may be denied.
    Note
    Note
    Denial Risk

    PA/QL triggers (denial risk)

    Drugs flagged with PA and/or QL may be denied if authorization is not obtained or quantity limits exceeded; check each product's Requirements/Limits to determine necessary actions.

    • Example: LYBALVI shows QL(30 EA per 30 days) and PA — both must be addressed when requesting coverage.
    Note
    Denial Risk

    PA/EX/OVM triggers (denial/exclusion implications)

    Drugs with PA, QL, or EX flags may trigger denials if PA is missing, QLs are exceeded, or exclusion criteria apply; ensure required authorizations or exceptions are in place.

    • Examples include meprobamate (PA), deferasirox (PA), tolvaptan (QL and PA), and products marked EX.
    Denial Risk

    Denial risk for missing PA or exceeding QL

    Prescriptions lacking required prior authorization where the formulary lists "PA" (or exceeding stated QLs) risk being denied; obtain PA or file an exception before dispensing to avoid coverage denial.

    • Examples called out: tadalafil tablets and testosterone pump gels may be denied without PA or if QLs are exceeded.
    Note
    Note
    Note
    Note

    Initial Therapy and Condition-Specific Criteria

    Migraine agents (initial coverage entries)

    Initial coverage entries for acute migraine agents include quantity limits and tier assignments.

    Migraine drug controls: Specific migraine agents have tier assignments and quantity limits (examples from formulary: UBRELVY QL(16 EA per 30 days); naratriptan QL values; sumatriptan injection QL(27 ML per 90 days)). Some migraine products are also marked PA — providers must meet the Requirements/Limits shown for coverage.

    No additional clinical step therapy rules provided in these chunks; follow per-drug Requirements/Limits for authorization

    Step Therapy Requirements and Records

    Coverage itemDescription / provider action
    Step therapy (ST)When a drug is marked 'ST' on the formulary, the member must try the specified preferred agent(s) first before the plan will cover an alternative. Documentation of trial/failure or an approved exception is required to obtain coverage for the subsequent agent.
    DocumentationPrescriber must provide evidence of trial and failure of the required agent(s) or justify an exception per the plan's step-therapy and prior authorization processes.
    Where to find detailsSee individual formulary entries and the plan’s introduction and utilization management documents for which drugs are subject to ST and for required supporting documentation.
    Formulary markerExamples in this extract (ST applied)
    ST flagEXXUA titration pack and EXXUA tablets — Requirements/Limits show 'ST' (QL and ST listed for EXXUA entries).
    ST flagTRINTELLIX tablets (5mg, 10mg, 20mg) — Requirements/Limits include 'ST' alongside QL.
    ST flagINVEGA SUSTENNA and INVEGA TRINZA injections — multiple strengths list QL and 'ST' in Requirements/Limits.
    ST flagPERSERIS injection — Requirements/Limits include QL(1 EA per 30 days) and 'ST'.
    ST flagREXULTI and VRAYLAR selected strengths — Requirements/Limits indicate QL and 'ST' for some strengths.
    ST flagPANCREAZE pancreatic enzyme strengths — Requirements/Limits include 'ST' for listed strengths.
    StatementInterpretation for this extract
    No explicit step therapy algorithms providedThe extract uses the 'ST' flag on product lines but does not include step-by-step algorithms or clinical sequences in the shown text; providers must refer to plan documentation/introduction or specific utilization management guides for full ST criteria.
    ST is applied where listedCoverage is conditional on meeting the per-product Requirements/Limits (ST, PA, QL) shown in the formulary lines. Specific ST sequences are not printed in this extract.
    ProductFormulary entry / ST note
    EXXUA TITRATION PACK / EXXUA tabletsRequirements/Limits = QL(32 EA per 14 days) and QL(31 EA per 31 days) respectively; both entries include 'ST' indicating step therapy applies.
    TRINTELLIX tablets (5mg, 10mg, 20mg)Requirements/Limits include QL values for each strength and 'ST' is shown, indicating a step-therapy requirement before coverage of alternatives.
    ObservationSource detail
    EXXUA products labeled 'ST'EXXUA TITRATION PACK and EXXUA TABLET entries list 'ST' in Requirements/Limits, demonstrating step therapy requirement for these products in the extract.
    ProductFormulary note
    EXXUA (titration pack and tablets)Requirements/Limits = QL(...) ; ST — entries explicitly mark EXXUA products with 'ST'.
    ProductFormulary note
    TRINTELLIX tablets (5mg/10mg/20mg)Requirements/Limits list quantity limits for each strength and include 'ST', indicating a step therapy requirement for TRINTELLIX in this extract.
    ObservationFormulary detail
    OVM and specialty oncology agentsMany oncology and supportive-care agents are flagged with PA and OVM; the extract notes OVM alongside PA but does not present explicit step-therapy sequences for these agents.
    PA-flagged specialty products may have additional requirementsEntries such as pomalidomide, thalidomide, and multiple antineoplastics show 'PA' and 'OVM' indicating additional utilization management beyond simple ST edits in this extract.
    Formulary markerExamples / products
    'ST' applies to several antipsychotic/behavioral agentsINVEGA SUSTENNA and INVEGA TRINZA injections, PERSERIS injection, REXULTI and selected strengths of other agents are shown with 'ST' in Requirements/Limits, indicating step therapy applies where flagged.
    Provider implicationWhen a product line shows 'ST', coverage requires meeting the step-therapy requirement or obtaining an approved exception; see the specific formulary entry for the product's QL and ST annotation.
    NoteRelevance to ST sequences
    No explicit ST sequences shownThe antiviral/coronavirus agent lines (e.g., PAXLOVID pack sizes) list multiple pack-size QLs but do not include step therapy sequences in the extract. ST presence is not shown for these entries.
    ObservationFormulary flags present
    Step therapy and PA referenced elsewhereSome agents in the extract are PA‑flagged and the planner notes indicate that step therapy or PA requirements may be defined in other formulary sections or utilization management documents; the shown lines do not always include full ST sequences.
    Product / markerCoverage implication
    Appetite suppressant products (examples)Entries such as benzphetamine, diethylpropion, phendimetrazine, phentermine are listed with 'EX' in Requirements/Limits, indicating exclusion or restricted coverage rather than ST; EX signals noncoverage per formulary definitions.
    ProductFormulary note
    PANCREAZE (multiple strengths)PANCREAZE capsule delayed-release particles (listed strengths) include 'ST' in Requirements/Limits indicating step therapy applies to these pancreatic enzyme preparations.
    ObservationExample entries
    Specialty/high-tier agents with PA or EXMultiple specialty or high-tier products in the extract are marked 'PA' or 'EX' (e.g., pomalidomide, thalidomide, many antineoplastics, appetite suppressants). Explicit step therapy sequences are not provided in the shown extract for these products.

    Quantity Limits (QL) by Product and Examples

    pioglitazone (example QL)
    pioglitazone example31 tablets per prescription (example quantity-limit guidance)
    ContextShown as an example of QL in formulary explanatory text
    various QL examples (EA/ML)
    31 EA per 31 days examplesMultiple ER and chronic oral therapies list QL(31 EA per 31 days)
    90-day EA examplesQL(360 EA per 90 days); QL(270 EA per 90 days); QL(180 EA per 90 days) used across many tablet classes
    Large ML examplesQL(3720 ML per 31 days); QL(372 ML per 31 days) shown for certain liquid opioid formulations
    buprenorphine/naloxone tablets and films QL examples
    Buprenorphine/naloxone tablets (8/2mg)QL(360 EA per 90 days)
    Buprenorphine/naloxone tablets (2/0.5mg)QL(630 EA per 90 days)
    Films (various strengths)Films mirror tablet QLs (360 or 630 EA per 90 days depending on strength)
    naloxone products QL examples
    KLOXXADO liquid 8mg/0.1mlQL(12 EA per 90 days)
    OPVEE solutionQL(12 EA per 90 days)
    Other naloxone injections/solutionsSome naloxone injections listed without QL; check specific entry
    linezolid suspension QL
    linezolid suspensionQL(1680 ML per 28 days)
    linezolid tabletQL(56 EA per 28 days)
    IV/injection formsInjection entries often list no QL or different QLs; see product line for details
    vancomycin capsules QL
    vancomycin injection/formsVarious injection strengths listed; check specific entry for QL
    vancomycin capsulesQL(360 EA per 90 days) for 125mg; QL(720 EA per 90 days) for 250mg
    ContextCapsule QLs provided to limit outpatient dispensing frequency
    BRIVIACT SOLUTION QL
    BRIVIACT solution 10mg/mlQL(620 ML per 31 days)
    Brivaracetam tabletQL(62 EA per 31 days)
    brivaracetam tablet QL
    brivaracetam tablet (multiple strengths)QL(62 EA per 31 days)
    Associated PATablet entries also list PA where applicable
    EPIDIOLEX SOLUTION QL
    EPIDIOLEX solution 100mg/mlQL(600 ML per 30 days)
    PAListed with PA in Requirements/Limits
    clobazam suspension QL
    clobazam suspension 2.5mg/mlQL(480 ML per 30 days)
    clobazam tablet 10/20mgQL(60 EA per 30 days)
    clobazam tablet QL
    clobazam tabletQL(60 EA per 30 days)
    PA/NDS notesEntries indicate PA and NDS for some forms — check product line
    memantine hydrochloride tablet QL
    memantine hydrochloride tabletQL(180 EA per 90 days)
    Titration packMEMANTINE HCL TITRATION PAK TABLET 0 — QL(98 EA per 365 days)
    ER capsulememantine hydrochloride ER capsule — QL(90 EA per 90 days)
    MEMANTINE HCL TITRATION PAK (QL value)
    MEMANTINE HCL TITRATION PAKQL(98 EA per 365 days)
    PurposeTitration pack has annual QL noted separately from regular tablet/capsule QLs
    memantine ER capsule QL (examples)
    memantine ER capsule (various strengths)QL(90 EA per 90 days)
    PAER capsules listed with PA in Requirements/Limits
    AIMOVIG injection QL examples
    AIMOVIG injection 140mg/mlQL(3 ML per 84 days)
    AIMOVIG injection 70mg/mlQL(6 ML per 84 days)
    AIMOVIG 70MG injection QL
    AIMOVIG 70mg injectionQL(6 ML per 84 days)
    AIMOVIG 140mg injectionQL(3 ML per 84 days)
    CRESEMBA capsule QL
    CRESEMBA capsule 74.5mgQL(175 EA per 31 days)
    Other CRESEMBA strengthsAlternate strengths list different QLs (e.g., 186mg entry QL(70 EA per 31 days))
    posaconazole dr tablet QL
    posaconazole DR tablet 100mgQL(93 EA per 31 days)
    PAEntry lists PA with QL
    UBRELVY QL example
    UBRELVY (ubrogepant)QL(16 EA per 30 days)
    PAListed with PA in Requirements/Limits
    rizatriptan QL example
    rizatriptan 5mg tabletQL(162 EA per 90 days)
    Alternate ODT strengthsRizatriptan ODT 10mg QL(81 EA per 90 days)
    ROZLYTREK QL
    ROZLYTREK capsule 200mgQL(93 EA per 31 days)
    PA/OVMListed with PA and OVM for specialty oncology management
    RUBRACA QL
    RUBRACA tablet (200/250/300mg)QL(124 EA per 31 days)
    PAListed with PA; OVM may apply
    INVEGA SUSTENNA injection QL (0.5 ML)
    INVEGA SUSTENNA injection 78mg/0.5mlQL(0.5 ML per 28 days)
    STMultiple INVEGA SUSTENNA strengths flagged ST (step therapy)
    INVEGA TRINZA QL (0.88 ML)
    INVEGA TRINZA injection 273mg/0.88mlQL(0.88 ML per 90 days)
    STFlagged ST; other TRINZA strengths list larger ML per 90 days
    lurasidone tablet QL (31 EA)
    lurasidone tablet (20–120mg)QL(31 EA per 31 days)
    higher strength80mg strength listed QL(62 EA per 31 days)
    LYBALVI tablet QL (30 EA)
    LYBALVI tabletQL(30 EA per 30 days); PA
    NoteListed as PA in Requirements/Limits alongside QL
    PERSERIS injection QL (1 EA)
    PERSERIS injection (120mg, 90mg)QL(1 EA per 30 days); ST
    ST noteFlagged ST (step therapy) in Requirements/Limits
    BIKTARVY tablet QL (31 EA)
    BIKTARVY tabletQL(31 EA per 31 days)
    HIV combination agentsMultiple HIV agents use 31 EA per 31 days QL convention
    oseltamivir capsule QL
    oseltamivir capsule 30mgQL(168 EA per 180 days)
    oseltamivir capsule 45/75mgQL(84 EA per 180 days)
    RepresentativeExamples of extended-period QLs for antiviral prophylaxis/treatment supplies
    LAGEVRIO capsule QL
    LAGEVRIO capsule 200mgQL(40 EA per 30 days)
    PAXLOVID therapy packQL(22–60 EA per 30 days) depending on pack option
    PAXLOVID therapy pack QL (various pack sizes)
    PAXLOVID therapy pack optionsQL(22 EA per 30 days); QL(40 EA per 30 days); QL(60 EA per 30 days) depending on pack
    Pack dosingPack descriptions include day 1 vs days 2–5 dosing and QL varies by pack type
    oseltamivir capsule 30mg QL
    oseltamivir capsule 30mg (alternate)QL(168 EA per 180 days)
    Use caseHigher EA counts reflect prophylaxis courses or multi-member supplies over 180 days
    oseltamivir 45/75mg QL
    oseltamivir 45/75mgQL(84 EA per 180 days)
    NotesStandard antiviral course QLs shown for 180-day window
    PAXLOVID therapy pack (various options)
    PAXLOVID pack options summaryQL(22–60 EA per 30 days) depending on pack; pack-level dosing noted per entry
    Provider noteDifferent pack QLs reflect dosing regimens and packaging
    liraglutide injection 6mg/ml QL
    liraglutide injection 6mg/mlQL(27 ML per 90 days)
    PA flagEntry pairs QL with PA (prior authorization)
    MOUNJARO injection QL
    MOUNJARO injection (various strengths)QL(2 ML per 28 days); PA
    Pack/strength noteQuantity expressed as mL per 28 days across strengths listed
    dabigatran capsule QL
    dabigatran etexilate capsuleQL(180 EA per 90 days)
    Anticoagulant examplesCommon QLs applied to oral anticoagulants for chronic therapy supplies
    ELIQUIS starter pack QL
    ELIQUIS starter pack therapy packQL(148 EA per 365 days)
    ContextStarter pack QL measured over 365 days for therapy initiation supplies
    rivaroxaban suspension QL
    rivaroxaban suspension reconstituted 1mg/mlQL(2700 ML per 90 days)
    UseLiquid suspension QL provided for patients requiring reconstituted forms
    eltrombopag packet QL
    eltrombopag olamine packet 25mgQL(186 EA per 31 days)
    Other packet strengthsAdditional packet strengths list QLs (e.g., 62 EA per 31 days)
    tranexamic acid tablet QL
    tranexamic acid tablet 650mgQL(90 EA per 63 days)
    ContextExample of a nonstandard period (63 days) used for a specific product
    amlodipine/atorvastatin combination QLs
    amlodipine/atorvastatin comboQL(180 EA per 90 days) or QL(360 EA per 90 days) depending on strength
    Strength-dependent QLsSome combination products use different QLs by strength/formulation
    PRALUENT injection QL
    PRALUENT injection 150mg/ML, 75mg/MLQL(2 ML per 28 days); PA
    Provider noteInjection volume QL combined with PA for specialty lipid‑lowering agent
    VYNDAMAX capsule QL
    VYNDAMAX capsule 61mgQL(31 EA per 31 days)
    PAEntry lists PA where applicable
    sacubitril/valsartan QL
    sacubitril/valsartanQL(180 EA per 90 days)
    ContextStandard 90-day EA limit for chronic heart-failure agent
    fenofibrate presentations QL
    fenofibrate presentationsQL(90 EA per 90 days) (varies by formulation)
    Variation noteDifferent fenofibrate formulations list differing QLs in the formulary
    PRALUENT injection QL (2 ML per 28 days)
    PRALUENT injection — summaryQL(2 ML per 28 days)
    ReiterationListed again in drug entries showing QL and PA together
    VERQUVO tablet QL
    VERQUVO tablet 10mgQL(30 EA per 30 days); PA
    Other strengthsVERQUVO 2.5/5mg listed QL(60 EA per 30 days); PA
    BETASERON injection QL
    BETASERON injection 0.3mgQL(14 EA per 28 days)
    MS injectable exampleTypical injection ML/EA QLs provided for multiple MS agents
    clobetasol cream QL
    clobetasol cream 0.05%QL(180 GM per 90 days)
    clobetasol foam 0.05%QL(300 GM per 90 days)
    clobetasol shampoo 0.05%QL(354 ML per 90 days)
    clobetasol foam QL
    clobetasol foam 0.05%QL(300 GM per 90 days)
    UseApplied to foam formulations in dermatology section
    clobetasol shampoo QL
    clobetasol shampoo 0.05%QL(354 ML per 90 days)
    Volume-based QLShampoo/solution products use ML-based QLs
    EBGLYSS injection QL
    EBGLYSS injection 250mg/2mlQL(8 ML per 28 days); PA
    Specialty injection noteInjection QL expressed in mL per 28 days and paired with PA
    OTEZLA XR QL
    OTEZLA XR 75mgQL(31 EA per 31 days); PA
    Initiation packOTEZLA 28-day initiation pack QL(28 EA per 28 days); PA
    tolvaptan QL
    tolvaptan 15mg (generic Jynarque)QL(31 EA per 31 days); PA
    tolvaptan 15mg (other/generic)QL(124 EA per 31 days) (formulation-specific listing)
    tolvaptan 30mgQL(62 EA per 31 days)
    tolvaptan generic Jynarque QL
    tolvaptan 15mg (generic Jynarque)QL(124 EA per 31 days); PA
    Samsca brandtolvaptan Samsca listing shows QL(31 EA per 31 days)
    tolvaptan Samsca QL
    tolvaptan Samsca 15mgQL(31 EA per 31 days)
    NotesBrand/generic distinctions reflected in differing QLs
    tolvaptan 30mg QL
    tolvaptan 30mgQL(62 EA per 31 days)
    Higher-strength QL30mg strength uses larger EA per 31 days limit
    sevelamer carbonate packet 0.8gm QL
    sevelamer carbonate packet 0.8gmQL(180 EA per 90 days)
    sevelamer carbonate packet 2.4gmQL(270 EA per 90 days)
    sevelamer carbonate tablet 800mgQL(1620 EA per 90 days)
    sevelamer carbonate packet 2.4gm QL
    sevelamer packet 2.4gmQL(270 EA per 90 days)
    Use casePacket QLs tailored to dosing frequency for phosphate binder therapy
    sevelamer carbonate tablet 800mg QL
    sevelamer tablet 800mgQL(1620 EA per 90 days)
    Large EA QLReflects multiple tablets per dose regimens
    LOKELMA packet 5GM QL
    LOKELMA packet 5gmQL(270 EA per 90 days)
    LOKELMA packet 10gmQL(94 EA per 90 days)
    LOKELMA packet 10GM QL
    LOKELMA packet 10gmQL(94 EA per 90 days)
    Packet size effectDifferent packet sizes use distinct QLs reflecting dose differences
    XIFAXAN tablet QL
    XIFAXAN 550mg tabletQL(93 EA per 31 days); PA
    IndicationUsed for hepatic encephalopathy/other GI indications; QL and PA applied
    VOWST capsule QL
    VOWST capsuleQL(12 EA per 30 days); PA
    NoteSmall EA per 30 days limit for this specialized capsule product
    MYRBETRIQ QL
    MYRBETRIQ ER 24hQL(90 EA per 90 days)
    oxybutynin ERQL(180 EA per 90 days)
    solifenacin succinateQL(180 EA per 90 days) for 5mg; QL(90 EA per 90 days) for 10mg
    oxybutynin ER QL
    oxybutynin ERQL(180 EA per 90 days)
    FormulationsER and solution forms listed with separate QLs
    solifenacin QL
    solifenacin succinateQL(180 EA per 90 days) for 5mg; QL(90 EA per 90 days) for 10mg
    Dose-dependent QLDifferent strengths may carry different QLs
    alfuzosin ER QL (31 EA)
    alfuzosin ER 10mgQL(90 EA per 90 days)
    BPH agent examplesCommon 90-day EA QL used for benign prostatic hypertrophy agents
    tadalafil 2.5mg QL
    tadalafil 2.5mgQL(180 EA per 90 days); PA
    tadalafil 5mgQL(90 EA per 90 days); PA
    tadalafil 5mg QL
    tadalafil 5mgQL(90 EA per 90 days); PA
    Use noteBoth strengths flagged PA in Requirements/Limits
    CAVERJECT QL
    CAVERJECT (various injectable forms)QL(6 EA per 30 days); some listed as EX (excluded) concurrently
    Dispensing noteSome injectable erectile dysfunction products limited and/or excluded per entry
    testosterone pump gel QL
    testosterone pump gel 1.62%QL(450 GM per 90 days); PA
    Alternate pump gel strength1% pump gel listed QL(900 GM per 90 days); PA
    DEPO-SUBQ PROVERA injection QL
    DEPO-SUBQ PROVERA 104 injectionQL(0.65 ML per defined period) — listed as 0.65 (per formulary entry)
    Administration noteDose/unit QL reflects injection volume supplied
    Billing Rule

    BIOSIMILAR (plan may substitute interchangeable biosimilars)

    The plan may substitute an interchangeable biosimilar for an original biological product and change coverage or tiering; pharmacies may substitute interchangeable biosimilars per state law without a new prescription.

    Definitions and Abbreviations

    Formulary / Drug List definition
    Formulary / Drug ListA list of covered drugs selected by the plan in consultation with health care providers; coverage depends on medical necessity, network pharmacy use, and plan rules
    AccessComplete listing available on plan website or by calling Customer Service
    Biosimilar / interchangeable biosimilar definition
    Biosimilar / interchangeable biosimilarA biosimilar is an alternative to an original biological product; interchangeable biosimilars may be substituted at the pharmacy without a new prescription depending on state law
    Substitution rulesSubstitutions follow state law; plan may add interchangeable biosimilars and change coverage/tiering
    PA definition
    Prior Authorization (PA)Approval required before filling certain drugs; without approval the plan may not cover the drug
    Provider actionPrescriber must submit supporting documentation per plan PA process when PA flag is shown
    QL definition
    Quantity Limit (QL)A formulary-specified maximum quantity the plan will cover in a defined time period (e.g., QL(360 EA per 90 days))
    UnitsExpressed as EA (each), ML (milliliters), GM (grams) per specified days (31/30/90/180/365)
    ST definition
    Step Therapy (ST)Requirement to try a specified drug first before another will be covered; if first drug fails, plan will cover next agent
    ApplicationApplied where formulary entry shows 'ST' (e.g., certain injectables/therapy packs)
    EX definition
    EX (Exclusion)Drug is not normally covered in the Medicare Prescription Drug Plan; amounts paid do not count toward total drug costs for catastrophic coverage
    ExampleSome topical and select products are listed EX in the formulary entries
    NDS definition
    NDS (Non-Extended Day Supply)Designation limiting supply to up to 30–31 days for certain drugs (e.g., many opioid analgesics, benzodiazepines)
    ImplicationNDS appears alongside QL to restrict extended fills
    OVM definition
    OVM (Oncology Value Management)Prior authorization required for antineoplastics and oncology supportive care drugs via the Oncology Value Management program administered by OncoHealth
    Provider requirementPhysician must submit additional information for coverage determinations
    QL (alternate chunk refs)
    Quantity Limit (QL) — formulary exampleShown in entries as QL(360 EA per 90 days) or similar expressions; defines max units per period
    Refer to introductionSymbols/abbreviations explained on the formulary introduction pages
    PA (alternate chunk refs)
    Prior Authorization (PA) — formulary exampleFlag 'PA' shown next to drug entries indicates approval required prior to coverage
    ConsequencesFailure to obtain PA may result in noncoverage or denial
    Prior Authorization (definition)
    Prior Authorization (definition) — detailedPlan requires prior authorization for certain drugs; prescriber must obtain approval before filling; lack of approval may mean plan will not cover the drug
    Where to find PA rulesPA and step therapy processes are detailed in plan documents and online resources
    Quantity Limit (definition)
    Quantity Limit (definition) — detailedMaximum dispensible quantity over the period shown in Requirements/Limits (e.g., QL(31 EA per 31 days)); expressed in EA, ML, or GM
    Implication for claimsClaims beyond QL may require PA or be limited at point of sale
    NDS definition (alternate)
    NDS (Non-Extended Day Supply) — noteLimits certain drugs to up to 30–31 day supply even if longer fills are generally available
    Common applicationApplied to many opioid analgesics and benzodiazepines as shown in entries
    QL (requirements/limits field example)
    QL — requirements/limits field exampleFormat examples: QL(16 EA per 30 days); QL(27 ML per 90 days); QL(108 EA per 90 days)
    InterpretationRead as maximum units (EA/ML/GM) authorized in the stated time window

    Background and Scope

    This formulary groups drugs by medical condition and provides coverage information including special requirements such as Prior Authorization (PA), Quantity Limits (QL), and Step Therapy (ST). Inclusion on the formulary indicates coverage subject to the drug line’s specified Requirements/Limits and plan rules.

    Biosimilars and Interchangeability

    Billing Rule

    BIOSIMILAR (plan may substitute interchangeable biosimilars)

    Plan may immediately add interchangeable biosimilars and change coverage or tiering of the original biological product; substitutions follow state law and may be made without a new prescription.